These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12593652)

  • 1. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
    Krovat EM; Langer T
    J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.
    Funk OF; Kettmann V; Drimal J; Langer T
    J Med Chem; 2004 May; 47(11):2750-60. PubMed ID: 15139753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists.
    Wei J; Wang S; Gao S; Dai X; Gao Q
    J Chem Inf Model; 2007; 47(2):613-25. PubMed ID: 17330954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-based molecular modeling study on a chemically diverse series of cholecystokinin-B/gastrin receptor antagonists: generation of predictive model.
    Chopra M; Mishra AK
    J Chem Inf Model; 2005; 45(6):1934-42. PubMed ID: 16309300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
    Debnath AK
    J Med Chem; 2003 Oct; 46(21):4501-15. PubMed ID: 14521412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore identification of alpha(1A)-adrenoceptor antagonists.
    Li MY; Tsai KC; Xia L
    Bioorg Med Chem Lett; 2005 Feb; 15(3):657-64. PubMed ID: 15664832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-I-converting enzyme inhibitory peptides: Chemical feature based pharmacophore generation.
    Wang Z; Zhang S; Jin H; Wang W; Huo J; Zhou L; Wang Y; Feng F; Zhang L
    Eur J Med Chem; 2011 Aug; 46(8):3428-33. PubMed ID: 21621881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
    Du LP; Tsai KC; Li MY; You QD; Xia L
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4771-7. PubMed ID: 15324906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists.
    Singh N; Nolan TL; McCurdy CR
    J Mol Graph Model; 2008 Sep; 27(2):131-9. PubMed ID: 18456526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
    Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
    J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
    Lu A; Zhang J; Yin X; Luo X; Jiang H
    Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
    Jain V; Saravanan P; Arvind A; Mohan CG
    Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the conditions in pharmacophore generation, scoring, and 3D database search for chemical feature-based pharmacophore models: one application study of ETA- and ETB-selective antagonists.
    Cucarull-González JR; Laggner C; Langer T
    J Chem Inf Model; 2006; 46(3):1439-55. PubMed ID: 16711764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first pharmacophore model for potent NF-kappaB inhibitors.
    Tsai KC; Teng LW; Shao YM; Chen YC; Lee YC; Li M; Hsiao NW
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5665-9. PubMed ID: 19726185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
    Zhang J; Yu K; Zhu W; Jiang H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3009-14. PubMed ID: 16530411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modeling of dual angiotensin II and endothelin A receptor antagonists.
    Xue WZ; Lü W; Zhou ZM; Wang ZL
    Yao Xue Xue Bao; 2009 Sep; 44(9):1002-8. PubMed ID: 20055175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.